{"id":"NCT01324128","sponsor":"Vifor Pharma","briefTitle":"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients","officialTitle":"An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-04","completion":"2012-10","firstPosted":"2011-03-28","resultsPosted":"2014-04-01","lastUpdate":"2014-04-24"},"enrollment":1059,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease Requiring Chronic Dialysis"],"interventions":[{"type":"DRUG","name":"PA21 (2.5 g tablet containing 500 mg iron)","otherNames":[]},{"type":"DRUG","name":"Sevelamer carbonate","otherNames":[]},{"type":"DRUG","name":"PA21-1 (1.25 g tablet containing 250 mg iron)","otherNames":[]}],"arms":[{"label":"PA21 (2.5 g tablet)","type":"EXPERIMENTAL"},{"label":"Sevelamer carbonate","type":"ACTIVE_COMPARATOR"},{"label":"PA21-1 (1.25 g tablet)","type":"OTHER"}],"summary":"This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate levels in these patients.","primaryOutcome":{"measure":"Change in Serum Phosphorus Levels From Week 24 to Week 27","timeFrame":"Week 24, Week 27","effectByArm":[{"arm":"PA21 (MD) Stage 2","deltaMin":0.25,"sd":0.23},{"arm":"PA21-1 (LD) Stage 2","deltaMin":1.92,"sd":0.23}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":15,"countries":["United States","Austria","Belgium","Croatia","Czechia","Germany","Latvia","Lithuania","Poland","Romania","Russia","Serbia","South Africa","Ukraine","United Kingdom"]},"refs":{"pmids":["40576086","29656600"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":129,"n":707},"commonTop":["Diarrhoea","Hyperphosphataemia","Faeces discoloured","Nausea","Hypertension"]}}